Brian L Pearlman

Summary

Publications

  1. ncbi request reprint Hepatitis C infection: a clinical review
    Brian L Pearlman
    Center For Hepatitis C, Atlanta Medical Center, Atlanta, GA 30312, USA
    South Med J 97:364-73; quiz 374. 2004
  2. doi request reprint Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care
    Brian L Pearlman
    Center For Hepatitis C, Atlanta Medical Center, Atlanta, GA 30309, USA
    Lancet Infect Dis 12:717-28. 2012
  3. ncbi request reprint The new cholesterol guidelines. Applying them in clinical practice
    Brian L Pearlman
    Department of Internal Medicine, Atlanta Medical Center, 285 Boulevard NE, Suite 140, Atlanta, GA 30312, USA
    Postgrad Med 112:13-6, 19-22, 25-6 passim. 2002
  4. doi request reprint Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more
    Brian L Pearlman
    Center For Hepatitis C, Atlanta Medical Center, Atlanta, Georgia 30312, USA
    Clin Infect Dis 52:889-900. 2011
  5. doi request reprint The IL-28 genotype: how it will affect the care of patients with hepatitis C virus infection
    Brian L Pearlman
    Center For Hepatitis C, Atlanta Medical Center, Atlanta, GA 30312, USA
    Curr Gastroenterol Rep 13:78-86. 2011
  6. doi request reprint Salicylate intoxication: a clinical review
    Brian L Pearlman
    Atlanta Medical Center, Atlanta, GA, USA
    Postgrad Med 121:162-8. 2009
  7. pmc Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it
    Brian L Pearlman
    Center For Hepatitis C, Atlanta Medical Center, Medical College of Georgia, Emory School of Medicine, 315 Boulevard NE Suite 200, Atlanta, Georgia 30312, United States
    World J Gastroenterol 14:3621-7. 2008
  8. ncbi request reprint Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders
    Brian L Pearlman
    Center For Hepatitis C, Atlanta Medical Center, Atlanta, GA 30309, USA
    Hepatology 46:1688-94. 2007
  9. ncbi request reprint Chronic hepatitis C therapy: changing the rules of duration
    Brian L Pearlman
    Center For Hepatitis C, Atlanta Medical Center, 30312, USA
    Clin Gastroenterol Hepatol 4:963-71. 2006
  10. ncbi request reprint Hepatitis C virus infection in African Americans
    Brian L Pearlman
    Center For Hepatitis C, Atlanta Medical Center, Medical College of Georgia, Atlanta, GA, USA
    Clin Infect Dis 42:82-91. 2006

Collaborators

Detail Information

Publications13

  1. ncbi request reprint Hepatitis C infection: a clinical review
    Brian L Pearlman
    Center For Hepatitis C, Atlanta Medical Center, Atlanta, GA 30312, USA
    South Med J 97:364-73; quiz 374. 2004
    ..Common side effects of therapy include neuropsychiatric symptoms, influenza-like symptoms and hematological abnormalities...
  2. doi request reprint Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care
    Brian L Pearlman
    Center For Hepatitis C, Atlanta Medical Center, Atlanta, GA 30309, USA
    Lancet Infect Dis 12:717-28. 2012
    ..Protease inhibitors are the first of many antiviral medications that will probably be combined in future interferon-free regimens...
  3. ncbi request reprint The new cholesterol guidelines. Applying them in clinical practice
    Brian L Pearlman
    Department of Internal Medicine, Atlanta Medical Center, 285 Boulevard NE, Suite 140, Atlanta, GA 30312, USA
    Postgrad Med 112:13-6, 19-22, 25-6 passim. 2002
    ..In this article, Dr Pearlman reviews the latest guidelines and offers case examples that demonstrate how to incorporate the recommendations routinely into clinical practice...
  4. doi request reprint Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more
    Brian L Pearlman
    Center For Hepatitis C, Atlanta Medical Center, Atlanta, Georgia 30312, USA
    Clin Infect Dis 52:889-900. 2011
    ..In summary, chronic HCV infection is curable with SVR attainment, and with cure comes improved liver histology and more favorable clinical outcomes, in comparison with patients who do not achieve the same therapeutic milestone...
  5. doi request reprint The IL-28 genotype: how it will affect the care of patients with hepatitis C virus infection
    Brian L Pearlman
    Center For Hepatitis C, Atlanta Medical Center, Atlanta, GA 30312, USA
    Curr Gastroenterol Rep 13:78-86. 2011
    ..Perhaps more importantly, the test can help the clinician personally tailor the duration and even the type of therapy that is most appropriate for an individual patient, newly or chronically infected with the hepatitis C virus...
  6. doi request reprint Salicylate intoxication: a clinical review
    Brian L Pearlman
    Atlanta Medical Center, Atlanta, GA, USA
    Postgrad Med 121:162-8. 2009
    ..The prognosis depends on prompt recognition and treatment. Delayed diagnosis results in increased morbidity and mortality, particularly in the elderly...
  7. pmc Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it
    Brian L Pearlman
    Center For Hepatitis C, Atlanta Medical Center, Medical College of Georgia, Emory School of Medicine, 315 Boulevard NE Suite 200, Atlanta, Georgia 30312, United States
    World J Gastroenterol 14:3621-7. 2008
    ..Based on data from both viral kinetic and clinical studies, therapy prolongation in slow responders may be a reasonable strategy to improve response rates in these treatment-refractory patients...
  8. ncbi request reprint Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders
    Brian L Pearlman
    Center For Hepatitis C, Atlanta Medical Center, Atlanta, GA 30309, USA
    Hepatology 46:1688-94. 2007
    ..Treatment extension does not seem to increase the rate of dose reduction or therapy discontinuation...
  9. ncbi request reprint Chronic hepatitis C therapy: changing the rules of duration
    Brian L Pearlman
    Center For Hepatitis C, Atlanta Medical Center, 30312, USA
    Clin Gastroenterol Hepatol 4:963-71. 2006
    ..This review focuses on the evidence supporting such treatment individualization and discusses potential treatment algorithm modifications...
  10. ncbi request reprint Hepatitis C virus infection in African Americans
    Brian L Pearlman
    Center For Hepatitis C, Atlanta Medical Center, Medical College of Georgia, Atlanta, GA, USA
    Clin Infect Dis 42:82-91. 2006
    ..Some of the postulated mechanisms for these disparate treatment responses and natural histories of infection are also reviewed...
  11. ncbi request reprint Hepatitis C treatment update
    Brian L Pearlman
    Center For Hepatitis C, Atlanta Medical Center, Atlanta, Georgia 30312, USA
    Am J Med 117:344-52. 2004
    ..Four broad groups of investigational therapeutic agents appear promising for future therapy: modified interferons and ribavirins, immunomodulators, viral life-cycle targets, and antifibrotic agents...
  12. doi request reprint Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor
    Brian L Pearlman
    Center For Hepatitis C, Atlanta Medical Center, Atlanta, GA Department of Graduate Medical Education, Atlanta Medical Center, Atlanta, GA Medical College of Georgia, Department of Medicine, Augusta, GA Emory University School of Medicine, Department of Medicine, Atlanta, GA
    Hepatology 59:71-7. 2014
    ..Conclusion: Protease inhibitor therapy could be obviated in genotype 1-infected treatment-naïve patients with low viral load at baseline who achieve undetectable viremia after 4 weeks of peginterferon/ribavirin...
  13. doi request reprint Coordinated evolution among hepatitis C virus genomic sites is coupled to host factors and resistance to interferon
    James Lara
    Molecular Epidemiology and Bioinformatics Laboratory, Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, USA
    In Silico Biol 11:213-24. 2011
    ..The data indicate host specificity of HCV evolution and suggest the application of these models to predict outcomes of IFN/RBV therapy...